Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.
about
Canadian practice guidelines for surgical intra-abdominal infectionsProportions of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in patients with surgical site infections in mainland China: a systematic review and meta-analysisOperating room environment and surgical site infections in arthroplasty proceduresThe elements of life and medicinesEarly oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.A randomized controlled trial of tea tree oil (5%) body wash versus standard body wash to prevent colonization with methicillin-resistant Staphylococcus aureus (MRSA) in critically ill adults: research protocol.Epidemiology of MRSA and current strategies in Europe and Japan.The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation.The standard one gram dose of vancomycin is not adequate prophylaxis for MRSASuccessful treatment for carriage of methicillin-resistant Staphylococcus aureus and importance of follow-upAntibiotic Resistance Profiling of Staphylococcus aureus Isolated from Clinical Specimens in a Tertiary Hospital from 2010 to 2012.Green silver nanoparticles of Phyllanthus amarus: as an antibacterial agent against multi drug resistant clinical isolates of Pseudomonas aeruginosa.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?Antimicrobial and antibiofilm activity of designed and synthesized antimicrobial peptide, KABT-AMP.Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo.Rapid intelligence and failing weapons: meeting the challenges of 21st century infections in the deployed clinical environment.Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia.Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysisEfficacy of the decolonization of methicillin-resistant Staphylococcus aureus carriers in clinical practiceASSOCIATION OF HIV WITH BREAST ABSCESS AND ALTERED MICROBIAL SUSCEPTIBILITY PATTERNS.Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.Review of new guidelines for prophylaxis and treatment of MRSA infections.Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection.Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community.Are glycopeptides still appropriate and convenient for empiric use?Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.Recent initiatives to reduce the spread of meticillin-resistant Staphylococcus aureus.Silver nanoparticles-modified films versus biomedical device-associated infections.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.Surveillance and management of multidrug-resistant microorganisms.The role of perioperative care in reducing rates of methicillin resistant Staphylococcus aureus.Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria.The prevalence of methicillin resistant organisms among pacemaker and defibrillator implant recipients.Methicillin-resistant Staphylococcus aureus sinusitis in nonhospitalized patients: a systematic review of prevalence and treatment outcomes.Targeting agr- and agr-Like quorum sensing systems for development of common therapeutics to treat multiple gram-positive bacterial infections.
P2860
Q24599288-DFEE5F70-7FA8-4F4C-8E7A-DC77C999290EQ27011335-5AC2CBA0-FCD1-4ACF-84FF-093F85A767E2Q28071852-1DFA4D58-9594-4CFF-8636-19D84C4ED530Q28649323-8291A428-5773-4769-B61F-A55255F00C6EQ30667465-F8BDDF21-F588-4631-9DF2-761C28762223Q33387963-E574E1F4-2658-4D6C-8B3E-AA5218E684EDQ33699782-A5DA48D3-5B3D-497F-B666-789ED0074203Q33778191-D2EC6DA5-A0CE-4A21-B421-79D6E9C4BFA5Q34024012-EC5A9C5C-C608-4DDF-8799-7625914D2DE4Q34108643-C2E0D5DF-AD70-40F7-8FE2-CBABDFB7E5FDQ34203319-5C44478B-5787-4829-95A2-ED9EE38C817AQ34306288-1AF9A357-A8E9-499C-BCA2-BC40291F88F3Q34478074-1ED1367B-2837-44E6-82B7-D4B9BCFA29CBQ34575804-914A8BDB-97F0-40F9-92CE-C8FD8E020368Q34708068-F3ED75E3-FD47-4C0A-8ED1-8F43A6F19970Q35004955-A6A5A0FF-2CBE-4276-9826-836595A40B24Q35012881-0948A136-3C5D-4124-A45B-916DA10CFB1DQ35408518-6D7A0469-D3BC-4683-9CA1-19DC94E38CE4Q36104490-AB8E388B-00D7-4510-B663-F0E82A849C04Q36384059-5BB6C09E-C72E-4228-9091-CDF258232B28Q36406438-B4AA4F07-FBF0-4EA1-8467-E62E978D8584Q36568337-228D8886-7A5A-40EE-B406-45F969374131Q36611653-D819D345-C3A3-47D8-B581-06499A805943Q36642946-E19BC78D-5C06-4CDB-B6DD-C3B8AE5FA18FQ36718474-C7CFE669-1B85-42AD-818E-19B7E346A296Q36968150-7F952E0F-E60C-4DB8-9454-4CBEAFCC619BQ37058032-F44A47D6-7C3F-4B03-9DEB-584990DD814EQ37109817-F1B3B2F0-7CF0-4114-8FAE-7DCEF479E073Q37333194-3B5DF598-BE30-45B0-9253-1BDB5B3C9346Q37413851-40EF01EF-6A29-43BD-8216-92D62C772142Q37544232-13701A68-BAE7-422D-AF4D-351B95A6CE48Q37781763-2573365C-951F-490D-93F6-80779308CF9CQ37800939-49BE35E7-6316-49D0-B1D5-8773A2118DF5Q37900838-88E553FF-AFF5-4DB4-A308-AC1DB41AFD7AQ37912231-182B9CDC-702D-46EB-9274-10D27B0170B6Q37977455-88C12BB4-9FAF-4812-A5EE-A8C8CBF3DBC0Q37983094-15C7174E-ABDF-4CC1-BD4F-6D2F7BBC87D1Q38020489-32770DE2-A4AE-4AE4-BB2C-0F78EDBD5EDEQ38025040-ADA815D9-2E3B-43A3-8156-A8650DE14833Q38100055-F8FF5BF8-EB13-49DD-BAA3-E3BA7B2656C2
P2860
Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Guidelines for the prophylaxis ...... s (MRSA) infections in the UK.
@ast
Guidelines for the prophylaxis ...... s (MRSA) infections in the UK.
@en
type
label
Guidelines for the prophylaxis ...... s (MRSA) infections in the UK.
@ast
Guidelines for the prophylaxis ...... s (MRSA) infections in the UK.
@en
prefLabel
Guidelines for the prophylaxis ...... s (MRSA) infections in the UK.
@ast
Guidelines for the prophylaxis ...... s (MRSA) infections in the UK.
@en
P2093
P2860
P356
P1476
Guidelines for the prophylaxis ...... s (MRSA) infections in the UK.
@en
P2093
Adam P Fraise
Curtis G Gemmell
David I Edwards
F Kate Gould
Geoff L Ridgway
Joint Working Party of the Bri ...... ion Control Nurses Association
Rod E Warren
P2860
P304
P356
10.1093/JAC/DKL017
P407
P577
2006-02-28T00:00:00Z